2025-524434-25-00Not yet recruitingPhase 2
Staging of gastric cancers by PET-FAPI
"Contribution of 68Ga-FAPI-46 PET-CT in the initial staging of gastric cancers eligible for curative treatment" "FAPGASTRO"
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Apr 2026
Brief summary (registry, in English)
In the study target population (stage ≥ II gastric adenocarcinomas or signet-ring cells adenocarcinomas of any stage, eligible for curative treatment), estimate the proportion of patients who present an appropriate change of TNM classification following the addition of 68Ga-FAPI-46 PET-CT to the reference examinations, during the initial staging (including laparoscopy)
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 18 Feb 2026
- Start date
- 1 Jun 2026
- Lead sponsor
- Centre Hospitalier Universitaire De Bordeaux
- Diseases
- Gastric and esophageal cancer
- EU CT number
- 2025-524434-25-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stomach (gastric) cancer who could have treatment meant to remove all of the disease. It adds a 68Ga-FAPI-46 PET-CT scan to the usual staging tests.
- Age
- Older than 18 years.
- Sex
- All sexes can join.
- Disease stage
- Stomach adenocarcinoma of stage II or higher, or signet-ring cell adenocarcinoma of any stage, where treatment meant to remove all of the disease may be needed.
- Earlier treatment
- Treatment before surgery (neoadjuvant treatment) must not have been started yet.
Main reasons for not taking part
- Cancer that has spread (M+) or is suspected to have spread to distant sites on standard tests
- Another active cancer in the past
- Known reaction to the radiopharmaceutical used in PET scans
- Pregnant or breastfeeding women
- Women who can have children and do not use effective contraception
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of other active cancer
- Known contraindication to a PET examination with injection of radiopharmaceuticals (hypersensitivity to the radiopharmaceutical drug and/or excipients)
Other
- Tumor M+ or with suspicion of distant metastasis on standard assessment
- Person deprived of liberty by judicial or administrative decision
- Neoadjuvant treatment already started
- Pregnant or breastfeeding woman
- Woman of childbearing capacity and not benefiting from effective contraception (HAS criterion)
- Person subject to a legal protection measure or unable to personally give consent
- Person in an emergency situation
- Exclusion period from another protocol
Who the study is looking for
- Gastric cancer: stage ≥ II gastric adenocarcinoma or signet-ring cell adenocarcinoma whatever the stage, potentially requiring curative treatment
- Age > 18 years old at time of signed consent
- Beneficiary of social security insurance
- Signed informed consent by the participant and the investigator
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Regional Du Cancer De Montpellier | Montpellier Cedex 5 | France | Not yet recruiting |
| Centre Hospitalier Universitaire De Bordeaux | Pessac Cedex | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.